1. Home
  2. Detail

@brickel.deals: #hair #cabello #beard #barba #tiktokshopcreatorpicks

BRICKEL DEALS
BRICKEL DEALS
Open In TikTok:
Region: US
Monday 07 September 2026 21:51:36 GMT
707
0
0
0

Music

Download

No Watermark .mp4 (6.65MB) No Watermark(HD) .mp4 (5.65MB) Watermark .mp4 (6.08MB) Music .mp3

Comments

There are no more comments for this video.
To see more videos from user @brickel.deals, please go to the Tikwm homepage.

Other Videos

#تغيير رقم الهاتف #viral #algeria #algerie🇩🇿 #algeroise
#تغيير رقم الهاتف #viral #algeria #algerie🇩🇿 #algeroise
Dương tỷ thật sự quá xinh đẹp #duonggian #khungbosonglai #thanbiphucto #mysteriousrecovery #tieuthuyet
Dương tỷ thật sự quá xinh đẹp #duonggian #khungbosonglai #thanbiphucto #mysteriousrecovery #tieuthuyet
Cree y ora por tu familia para que lleguen a los pies de Cristo.
Cree y ora por tu familia para que lleguen a los pies de Cristo.
❤️‍🩹 #luisenrique#xana#parissaintgermain#championsleague
❤️‍🩹 #luisenrique#xana#parissaintgermain#championsleague
❤️ GLP-1s aren’t just a weight-loss story — some of the strongest data we have are cardiovascular. In the SELECT trial, semaglutide reduced major cardiovascular events in adults with overweight/obesity and established cardiovascular disease without diabetes. And this isn’t one isolated study. Cardiovascular outcome trials including SUSTAIN-6, LEADER and SOUL have also demonstrated cardiovascular benefits of GLP-1 therapies in specific high-risk populations. In SOUL, oral semaglutide was associated with a 14% relative reduction in major cardiovascular events versus placebo. The GLP-1 conversation is getting much bigger than the scale. 🫀 Educational only. Benefits vary by medication and patient population. #GLP1 #HeartHealth #hormonehealth #MedicalEducation #Menopause
❤️ GLP-1s aren’t just a weight-loss story — some of the strongest data we have are cardiovascular. In the SELECT trial, semaglutide reduced major cardiovascular events in adults with overweight/obesity and established cardiovascular disease without diabetes. And this isn’t one isolated study. Cardiovascular outcome trials including SUSTAIN-6, LEADER and SOUL have also demonstrated cardiovascular benefits of GLP-1 therapies in specific high-risk populations. In SOUL, oral semaglutide was associated with a 14% relative reduction in major cardiovascular events versus placebo. The GLP-1 conversation is getting much bigger than the scale. 🫀 Educational only. Benefits vary by medication and patient population. #GLP1 #HeartHealth #hormonehealth #MedicalEducation #Menopause
#xuhuong #fyp
#xuhuong #fyp

About

Legal